

Suppl. Table 1. Baseline characteristics

Age (yr ± SD)	39.5 (9.9)
Duration since MS diagnosis (yr ± SD)	6.7 (5.9)
Sex (f/m)	65/48
Previous DMT use before fingolimod start (no. (%))	91 (80.5)
Interferon beta	45 (39.8)
Glatirameracetat	27 (23.9)
Natalizumab	14 (12.4)
Others	5 (4.4)
None previous DMT use (no. (%))	22 (19.5)
BMI (± SD)	25.0 (4.7)
EDSS (± SD)	2.8 (1.4)

Baseline characteristics of evaluated patients are depicted. DMT, disease modifying treatment. Other previous treatments included: Azathioprin (2), Laquinimod (3). During a standardized treatment switch procedure, injectables were stopped 2 weeks before fingolimod start, natalizumab was stopped 12 weeks before fingolimod start and other DMTs at least 6 months before fingolimod start. Yr, year; SD, standard deviation; f, female; m, male; no, number.